The ISSCR Shares Comments on the European Medicines Agency's Network Strategy to 2025

The ISSCR shared comments with the European Medicines Agency (EMA) related to its Network Strategy 2025. This included support for the crucial role of EMA and national regulators in overseeing the development of new products and offer a few recommendations to ensure that new products are proven safe and effective before being marketed to patients.

Among other points made, the ISSCR recognized that the draft network strategy acknowledges the lack of consistency across the EU for how some products are regulated, and encouraged the EMA to prioritize the consistent application of the regulations and enforcement to prevent the premature commercialization of stem cell-based products and other regenerative medicines.

Read the letter.